Cancer survivor Laurie Adami reflects on her experience participating in a clinical trial that ultimately contributed to the March 2021 approval of a CAR-T cell therapy for follicular lymphoma.

by Laurie Adami

Experts discussed how the cancer community can share accurate information and increase confidence in COVID-19 vaccines, both among people with cancer and the general population.

by Kevin McLaughlin

In recent months, drugmakers have announced they are withdrawing indications for four immune checkpoint inhibitors in consultation with the Food and Drug Administration. What does this mean for patients who are taking these drugs?

by Anna Goshua

Two immune checkpoint inhibitors are now approved for treatment of some people with advanced breast cancer, but trial results have raised some questions.

by Anna Goshua

The Food and Drug Administration approved an immunotherapy drug for tumors with high tumor mutational burden regardless of tumor type. But some medical oncologists say it's not clear the biomarker is valid across all cancer types.

by Anna Azvolinsky

Patient advocates with metastatic breast cancer argue that dosing of treatments for their disease should be more personalized and take into account quality of life.

by Marcus A. Banks

A trial of the targeted therapy Tagrisso (osimertinib) for early-stage lung cancer finds that patients who take it go longer without having a cancer recurrence. Whether that should change clinical practice is under discussion.

by Ashley P. Taylor

Drug developers behind currently approved checkpoint inhibitors discuss the pros and cons of competition in the field.

by Kate Yandell

The Cancer Today editorial staff selects some of the most interesting and impactful reporting, research and perspectives of 2018.

by Cancer Today Staff

Medical oncologist and sarcoma specialist George D. Demetri explains the significance of the recent approval of the oral drug Vitrakvi based on tumor genetics.

by Anna Azvolinsky